nach oben

Current Treatment Options in Oncology

Erschienen in:

01.02.2020 | Palliative and Supportive Care (MP Davis, Section Editor)

Cancer-Related Fatigue: Causes and Current Treatment Options

verfasst von: Melissa S.Y. Thong, Cornelis J. F. van Noorden, Karen Steindorf, Volker Arndt

Erschienen in: Current Treatment Options in Oncology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Opinion statement

Cancer-related fatigue (CRF) is a problem for a significant proportion of cancer survivors during and after active cancer treatment. However, CRF is underdiagnosed and undertreated. Interventions are available for CRF although there is no gold standard. Based on current level of evidence, exercise seems to be most effective in preventing or ameliorating CRF during the active- and posttreatment phases.

1.•

National Coalition for Cancer Survivorship. Cancer survivorship survey: findings from an online survey of adult cancer patients. 2019. https://www.canceradvocacy.org/wp-content/uploads/2019/09/NCCS-Survivorship-Survey-Final-Report.pdf. Accessed 16 October 2019 Fatigue was identified as one of the most severe side effects experienced by survivors but is not adequately addressed by health care providers.

Cheng KK, Lee DT. Effects of pain, fatigue, insomnia, and mood disturbance on functional status and quality of life of elderly patients with cancer. Crit Rev Oncol Hematol. 2011;78:127-37. https://doi.org/10.1016/j.critrevonc.2010.03.002.CrossRefPubMed

Arndt V, Stegmaier C, Ziegler H, Brenner H. A population-based study of the impact of specific symptoms on quality of life in women with breast cancer 1 year after diagnosis. Cancer. 2006;107:2496-503. https://doi.org/10.1002/cncr.22274.CrossRefPubMed

Duijts SF, van Egmond MP, Spelten E, van Muijen P, Anema JR, van der Beek AJ. Physical and psychosocial problems in cancer survivors beyond return to work: a systematic review. Psychooncology. 2014;23:481-92. https://doi.org/10.1002/pon.3467.CrossRefPubMed

Ekenga CC, Pérez M, Margenthaler JA, Jeffe DB. Early-stage breast cancer and employment participation after 2 years of follow-up: a comparison with age-matched controls. Cancer. 2018;124:2026-35. https://doi.org/10.1002/cncr.31270.CrossRef

Behringer K, Goergen H, Müller H, Thielen I, Brillant C, Kreissl S, et al. Cancer-related fatigue in patients with and survivors of Hodgkin lymphoma: the impact on treatment outcome and social reintegration. J Clin Oncol. 2016;34:4329-37. https://doi.org/10.1200/jco.2016.67.7450.CrossRefPubMed

Heins MJ, Korevaar JC, Rijken PM, Schellevis FG. For which health problems do cancer survivors visit their general practitioner? Eur J Cancer. 2013;49:211-8. https://doi.org/10.1016/j.ejca.2012.07.011.CrossRefPubMed

Groenvold M, Petersen MA, Idler E, Bjorner JB, Fayers PM, Mouridsen HT. Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients. Breast Cancer Res Treat. 2007;105:209-19. https://doi.org/10.1007/s10549-006-9447-x.CrossRefPubMed

Adam S, van de Poll-Franse LV, Mols F, Ezendam NPM, de Hingh I, Arndt V, et al. The association of cancer-related fatigue with all-cause mortality of colorectal and endometrial cancer survivors: results from the population-based PROFILES registry. Cancer Med. 2019;8:3227-36. https://doi.org/10.1002/cam4.2166.CrossRefPubMedPubMedCentral

10.

Santos JC, Pyter LM. Neuroimmunology of behavioral comorbidities associated with cancer and cancer treatments. Front Immunol. 2018;9. https://doi.org/10.3389/fimmu.2018.01195.

11.

National Coalition for Cancer Survivorship. http://www.canceradvocacy.org/. Accessed 26 September 2017.

12.

Schmidt ME, Wiskemann J, Schneeweiss A, Potthoff K, Ulrich CM, Steindorf K. Determinants of physical, affective, and cognitive fatigue during breast cancer therapy and 12 months follow-up. Int J Cancer. 2018;142:1148-57. https://doi.org/10.1002/ijc.31138.CrossRefPubMed

13.

Zhao F, Cella D, Manola J, DiPaola RS, Wagner LI, Haas NSB. Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial. Support Care Cancer. 2018;26:1889-95. https://doi.org/10.1007/s00520-017-4027-7.CrossRefPubMed

14.

Reinertsen KV, Engebraaten O, Loge JH, Cvancarova M, Naume B, Wist E, et al. Fatigue during and after breast cancer therapy—a prospective study. J Pain Symptom Manag. 2017;53:551-60. https://doi.org/10.1016/j.jpainsymman.2016.09.011.CrossRef

15.

Velikova G, Williams LJ, Willis S, Dixon JM, Loncaster J, Hatton M, et al. Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. Lancet Oncol. 2018;19:1516-29. https://doi.org/10.1016/S1470-2045(18)30515-1.CrossRefPubMed

16.

Crossnohere NL, Richardson DR, Reinhart C, O'Donoghue B, Love SM, Smith BD, et al. Side effects from acute myeloid leukemia treatment: results from a national survey. Curr Med Res Opin. 2019:1-6. https://doi.org/10.1080/03007995.2019.1631149.CrossRef

17.

Frick MA, Vachani CC, Hampshire MK, Bach C, Arnold-Korzeniowski K, Metz JM, et al. Survivorship after lower gastrointestinal cancer: patient-reported outcomes and planning for care. Cancer. 2017;123:1860-8. https://doi.org/10.1002/cncr.30527.CrossRefPubMed

18.

Roila F, Fumi G, Ruggeri B, Antonuzzo A, Ripamonti C, Fatigoni S, et al. Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian network for supportive care in cancer (NICSO). Support Care Cancer. 2019;27:1041-7. https://doi.org/10.1007/s00520-018-4393-9.CrossRefPubMed

19.

Wang XS, Zhao F, Fisch MJ, O'Mara AM, Cella D, Mendoza TR, et al. Prevalence and characteristics of moderate to severe fatigue: a multicenter study in cancer patients and survivors. Cancer. 2014;120:425-32. https://doi.org/10.1002/cncr.28434.CrossRefPubMed

20.

Bower JE, Wiley J, Petersen L, Irwin MR, Cole SW, Ganz PA. Fatigue after breast cancer treatment: biobehavioral predictors of fatigue trajectories. Health Psychol. 2018;37:1025-34. https://doi.org/10.1037/hea0000652.CrossRefPubMedPubMedCentral

21.

Langston B, Armes J, Levy A, Tidey E, Ream E. The prevalence and severity of fatigue in men with prostate cancer: a systematic review of the literature. Support Care Cancer. 2013;21:1761-71. https://doi.org/10.1007/s00520-013-1751-5.CrossRefPubMed

22.

Mao H, Bao T, Shen X, Li Q, Seluzicki C, Im E-O, et al. Prevalence and risk factors for fatigue among breast cancer survivors on aromatase inhibitors. Eur J Cancer. 2018;101:47-54. https://doi.org/10.1016/j.ejca.2018.06.009.CrossRefPubMedPubMedCentral

23.

Gavin AT, Drummond FJ, Donnelly C, O'Leary E, Sharp L, Kinnear HR. Patient-reported ‘ever had’ and ‘current’ long-term physical symptoms after prostate cancer treatments. BJU Int. 2015;116:397-406. https://doi.org/10.1111/bju.13036.CrossRefPubMedPubMedCentral

24.

Davis LE, Bubis LD, Mahar AL, Li Q, Sussman J, Moody L, et al. Patient-reported symptoms after breast cancer diagnosis and treatment: a retrospective cohort study. Eur J Cancer. 2018;101:1-11. https://doi.org/10.1016/j.ejca.2018.06.006.CrossRefPubMed

25.

Koole JL, Bours MJL, Breedveld-Peters JJL, van Roekel EH, Breukink SO, Janssen-Heijnen MLG, et al. Is dietary supplement use longitudinally associated with fatigue in stage I-III colorectal cancer survivors? Clin Nutr. 2019. https://doi.org/10.1016/j.clnu.2018.12.037.CrossRef

26.

Matias M, Baciarello G, Neji M, Di Meglio A, Michiels S, Partridge AH, et al. Fatigue and physical activity in cancer survivors: a cross-sectional population-based study. Cancer Med. 2019;8:2535-44. https://doi.org/10.1002/cam4.2060.CrossRefPubMedPubMedCentral

27.

Bøhn S-KH, Thorsen L, Kiserud CE, Fosså SD, Lie HC, Loge JH, et al. Chronic fatigue and associated factors among long-term survivors of cancers in young adulthood. Acta Oncol. 2019;58:753-62. https://doi.org/10.1080/0284186X.2018.1557344.CrossRefPubMed

28.

Steen R, Dahl AA, Hess SL, Kiserud CE. A study of chronic fatigue in Norwegian cervical cancer survivors. Gynecol Oncol. 2017;146:630-5. https://doi.org/10.1016/j.ygyno.2017.05.028.CrossRefPubMed

29.

Reinertsen KV, Cvancarova M, Loge JH, Edvardsen H, Wist E, Fosså SD. Predictors and course of chronic fatigue in long-term breast cancer survivors. J Cancer Surviv. 2010;4:405-14. https://doi.org/10.1007/s11764-010-0145-7.CrossRefPubMedPubMedCentral

30.

Smeland KB, Loge JH, Aass HCD, Aspelin T, Bersvendsen H, Bolstad N, et al. Chronic fatigue is highly prevalent in survivors of autologous stem cell transplantation and associated with IL-6, neuroticism, cardiorespiratory fitness, and obesity. Bone Marrow Transplant. 2019;54:607-10. https://doi.org/10.1038/s41409-018-0342-y.CrossRefPubMed

31.

Husson O, Mols F, van de Poll-Franse L, de Vries J, Schep G, Thong MSY. Variation in fatigue among 6011 (long-term) cancer survivors and a normative population: a study from the population-based PROFILES registry. Support Care Cancer. 2015;23:2165-74. https://doi.org/10.1007/s00520-014-2577-5.CrossRefPubMed

32.

Arndt V, Koch-Gallenkamp L, Jansen L, Bertram H, Eberle A, Holleczek B, et al. Quality of life in long-term and very long-term cancer survivors versus population controls in Germany. Acta Oncol. 2017;56:190-7. https://doi.org/10.1080/0284186x.2016.1266089.CrossRefPubMed

33.

Gresham G, Dy SM, Zipunnikov V, Browner IS, Studenski SA, Simonsick EM, et al. Fatigability and endurance performance in cancer survivors: analyses from the Baltimore longitudinal study of aging. Cancer. 2018;124:1279-87. https://doi.org/10.1002/cncr.31238.CrossRefPubMed

34.

Tibubos AN, Ernst M, Brähler E, Fischbeck S, Hinz A, Blettner M, et al. Fatigue in survivors of malignant melanoma and its determinants: a register-based cohort study. Support Care Cancer. 2019;27:2809-18. https://doi.org/10.1007/s00520-018-4587-1.CrossRefPubMed

35.

Poort H, Kaal SEJ, Knoop H, Jansen R, Prins JB, Manten-Horst E, et al. Prevalence and impact of severe fatigue in adolescent and young adult cancer patients in comparison with population-based controls. Support Care Cancer. 2017;25:2911-8. https://doi.org/10.1007/s00520-017-3746-0.CrossRefPubMedPubMedCentral

36.

Spathis A, Hatcher H, Booth S, Gibson F, Stone P, Abbas L, et al. Cancer-related fatigue in adolescents and young adults after cancer treatment: persistent and poorly managed. J Adolesc Young Adult Oncol. 2017;6:489-93. https://doi.org/10.1089/jayao.2017.0037.CrossRefPubMedPubMedCentral

37.

Younger E, Husson O, Bennister L, Whelan J, Wilson R, Roast A, et al. Age-related sarcoma patient experience: results from a national survey in England. BMC Cancer. 2018;18:991. https://doi.org/10.1186/s12885-018-4866-8.CrossRefPubMedPubMedCentral

38.

Mols F, Schoormans D, Smit JWA, Netea-Maier RT, Links TP, van der Graaf WTA, et al. Age-related differences in health-related quality of life among thyroid cancer survivors compared with a normative sample: results from the PROFILES registry. Head Neck. 2018;40:2235-45. https://doi.org/10.1002/hed.25325.CrossRefPubMed

39.••

NCCN Clinical Practice Guidelines in Oncology. Cancer-related fatigue version 1.2019. 2019. www.nccn.org. Accessed 11 July 2019. Most current guidelines on CRF

40.

de Raaf PJ. Cancer-related fatigue: a multidimensional approach. Rotterdam, P.J. de Raaf, 2013.

41.

de Raaf PJ, de Klerk C, van der Rijt CC. Elucidating the behavior of physical fatigue and mental fatigue in cancer patients: a review of the literature. Psychooncology. 2013;22:1919-29. https://doi.org/10.1002/pon.3225.CrossRefPubMed

42.

de Raaf PJ, de Klerk C, Timman R, Hinz A, van der Rijt CC. Differences in fatigue experiences among patients with advanced cancer, cancer survivors, and the general population. J Pain Symptom Manag. 2012;44:823-30. https://doi.org/10.1016/j.jpainsymman.2011.12.279.CrossRef

43.

Thong MSY, Mols F, van de Poll-Franse LV, Sprangers MAG, van der Rijt CCD, Barsevick AM, et al. Identifying the subtypes of cancer-related fatigue: results from the population-based PROFILES registry. J Cancer Surviv. 2018;12:38-46. https://doi.org/10.1007/s11764-017-0641-0.CrossRefPubMed

44.

• O’Higgins CM, Brady B, O’Connor B, Walsh D, Reilly RB. The pathophysiology of cancer-related fatigue: current controversies. Support Care Cancer. 2018;26:3353-64. https://doi.org/10.1007/s00520-018-4318-7. Provides a narrative overview of central and peripheral pathophysiologic hypotheses underlying CRF.CrossRefPubMed

45.

James S, Wright P, Scarlett C, Young T, Jamal H, Verma R. Cancer-related fatigue: results from patient experience surveys undertaken in a UK regional cancer centre. Support Care Cancer. 2015;23:2089-95. https://doi.org/10.1007/s00520-014-2565-9.CrossRefPubMed

46.

Smith TG, Troeschel AN, Castro KM, Arora NK, Stein K, Lipscomb J, et al. Perceptions of patients with breast and colon cancer of the management of cancer-related pain, fatigue, and emotional distress in community oncology. J Clin Oncol. 2019;37:1666-76. https://doi.org/10.1200/jco.18.01579.CrossRefPubMedPubMedCentral

47.

Ripamonti CI, Antonuzzo A, Bossi P, Cavalieri S, Roila F, Fatigoni S. Fatigue, a major still underestimated issue. Curr Opin Oncol. 2018;30:219-25. https://doi.org/10.1097/cco.0000000000000451.CrossRefPubMed

48.

Thompson LMA, Bobonis BM. Distinguishing depressive symptoms from similar cancer-related somatic symptoms: implications for assessment and management of major depression after breast cancer. South Med J. 2017;110:667-72. https://doi.org/10.14423/SMJ.0000000000000705.CrossRefPubMed

49.

Schellekens MPJ, Wolvers MDJ, Schroevers MJ, Bootsma TI, Cramer AOJ, van der Lee ML. Exploring the interconnectedness of fatigue, depression, anxiety and potential risk and protective factors in cancer patients: a network approach. J Behav Med. 2019:1-11. https://doi.org/10.1007/s10865-019-00084-7.

50.

Smet S, Pötter R, Haie-Meder C, Lindegaard JC, Schulz-Juergenliemk I, Mahantshetty U, et al. Fatigue, insomnia and hot flashes after definitive radiochemotherapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: an analysis from the EMBRACE study. Radiother Oncol. 2018;127:440-8. https://doi.org/10.1016/j.radonc.2018.03.009.CrossRefPubMed

51.

Agasi-Idenburg C, Velthuis M, Wittink H. Quality criteria and user-friendliness in self-reported questionnaires on cancer-related fatigue: a review. J Clin Epidemiol. 2010;63:705-11. https://doi.org/10.1016/j.jclinepi.2009.08.027.CrossRefPubMed

52.

Minton O, Stone P. A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Ann Oncol. 2009;20. https://doi.org/10.1093/annonc/mdn537.CrossRef

53.

Weis J, Tomaszewski KA, Hammerlid E, Ignacio Arraras J, Conroy T, Lanceley A, et al. International psychometric validation of an EORTC quality of life module measuring cancer related fatigue (EORTC QLQ-FA12). JNCI. 2017;109. https://doi.org/10.1093/jnci/djw273.

54.

• Pearson EJM, Morris ME, McKinstry CE. Cancer related fatigue: implementing guidelines for optimal management. BMC Health Serv Res. 2017;17:496. https://doi.org/10.1186/s12913-017-2415-9. Barriers to the implementation of CRF guidelines are identified and recommendations to overcome barriers are discussed.CrossRefPubMedPubMedCentral

55.

Fernandez C, Firdous S, Jehangir W, Behm B, Mehta Z, Berger A, et al. Cancer-related fatigue: perception of effort or task failure? Am J Hosp Palliat Care. 2019;1049909119849420. https://doi.org/10.1177/1049909119849420.CrossRef

56.

Kisiel-Sajewicz K, Davis MP, Siemionow V, Seyidova-Khoshknabi D, Wyant A, Walsh D, et al. Lack of muscle contractile property changes at the time of perceived physical exhaustion suggests central mechanisms contributing to early motor task failure in patients with cancer-related fatigue. J Pain Symptom Manag. 2012;44:351-61. https://doi.org/10.1016/j.jpainsymman.2011.08.007.CrossRef

57.

• Davis MP, Walsh D. Mechanisms of fatigue. J Support Oncol. 2010;8:164-74. Overview of central and peripheral mechanisms of CRF.PubMed

58.•

Yang S, Chu S, Gao Y, Ai Q, Liu Y, Li X, et al. A narrative review of cancer-related fatigue (CRF) and its possible pathogenesis. Cells. 2019;8. https://doi.org/10.3390/cells8070738. Provides a narrative overview of possible pathogenesis of CRF involving mitochondrial dysfunction, the HPA axis and immune/inflammation activation.CrossRef

59.

Cleeland CS, Bennet GJ, Dantzer R, Dougherty PM, Dunn AJ, Meyers CA. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003;97. https://doi.org/10.1002/cncr.11382.CrossRef

60.

Saligan LN, Olson K, Filler K, Larkin D, Cramp F, Yennurajalingam S, et al. The biology of cancer-related fatigue: a review of the literature. Support Care Cancer. 2015;23:2461-78. https://doi.org/10.1007/s00520-015-2763-0.CrossRefPubMedPubMedCentral

61.•

Bower JE. Cancer-related fatigue: mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014;11:597-609. https://doi.org/10.1038/nrclinonc.2014.127 This review touches on the mechanisms (focus on inflammation), risk factors, and interventions for CRF.CrossRefPubMedPubMedCentral

62.

Kim S, Miller BJ, Stefanek ME, Miller AH. Inflammation-induced activation of the indoleamine 2,3-dioxygenase pathway: relevance to cancer-related fatigue. Cancer. 2015;121:2129-36. https://doi.org/10.1002/cncr.29302.CrossRefPubMed

63.

Vichaya EG, Chiu GS, Krukowski K, Lacourt TE, Kavelaars A, Dantzer R, et al. Mechanisms of chemotherapy-induced behavioral toxicities. Front Neurosci. 2015;9. https://doi.org/10.3389/fnins.2015.00131.

64.

Schmidt ME, Semik J, Habermann N, Wiskemann J, Ulrich CM, Steindorf K. Cancer-related fatigue shows a stable association with diurnal cortisol dysregulation in breast cancer patients. Brain Behav Immun. 2016;52:98-105. https://doi.org/10.1016/j.bbi.2015.10.005.CrossRefPubMed

65.

• Charalambous A, Berger AM, Matthews E, Balachandran DD, Papastavrou E, Palesh O. Cancer-related fatigue and sleep deficiency in cancer care continuum: concepts, assessment, clusters, and management. Support Care Cancer. 2019;27:2747-53. https://doi.org/10.1007/s00520-019-04746-9. Provides an overview of the relationships of CRF with sleep problems and depression.CrossRefPubMed

66.

Liu L, Rissling M, Neikrug A, Fiorentino L, Natarajan L, Faierman M, et al. Fatigue and circadian activity rhythms in breast cancer patients before and after chemotherapy: a controlled study. Fatigue. 2013;1:12-26. https://doi.org/10.1080/21641846.2012.741782.CrossRefPubMedPubMedCentral

67.

Ratcliff CG, Lam CY, Arun B, Valero V, Cohen L. Ecological momentary assessment of sleep, symptoms, and mood during chemotherapy for breast cancer. Psychooncology. 2014;23:1220-8. https://doi.org/10.1002/pon.3525.CrossRefPubMedPubMedCentral

68.

Bower JE, Asher A, Garet D, Petersen L, Ganz PA, Irwin MR, et al. Testing a biobehavioral model of fatigue before adjuvant therapy in women with breast cancer. Cancer. 2019;125:633-41. https://doi.org/10.1002/cncr.31827.CrossRefPubMed

69.

Kreissl S, Mueller H, Goergen H, Mayer A, Brillant C, Behringer K, et al. Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin study group. Lancet Oncol. 2016;17:1453-62. https://doi.org/10.1016/S1470-2045(16)30093-6.CrossRefPubMed

70.

Nelson AM, Gonzalez BD, Jim HSL, Cessna JM, Sutton SK, Small BJ, et al. Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Support Care Cancer. 2016;24:4159-66. https://doi.org/10.1007/s00520-016-3241-z.CrossRefPubMedPubMedCentral

71.

Oerlemans S, Mols F, Issa DE, Pruijt JHFM, Peters WG, Lybeert M, et al. A high level of fatigue among long-term survivors of non-Hodgkin’s lymphoma: results from the longitudinal population-based PROFILES registry in the south of the Netherlands. Haematologica. 2013;98:479-86. https://doi.org/10.3324/haematol.2012.064907.CrossRefPubMedPubMedCentral

72.

Guinan EM, Bennett AE, Doyle SL, O’Neill L, Gannon J, Foley G, et al. Measuring the impact of oesophagectomy on physical functioning and physical activity participation: a prospective study. BMC Cancer. 2019;19:682. https://doi.org/10.1186/s12885-019-5888-6.CrossRefPubMedPubMedCentral

73.

Abrahams HJG, Gielissen MFM, Schmits IC, Verhagen CAHHVM, Rovers MM, Knoop H. Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12 327 breast cancer survivors. Ann Oncol. 2016;27:965-74. https://doi.org/10.1093/annonc/mdw099.CrossRefPubMed

74.

Vardy JL, Dhillon HM, Pond GR, Renton C, Dodd A, Zhang H, et al. Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study. Ann Oncol. 2016;27:1761-7. https://doi.org/10.1093/annonc/mdw252.CrossRefPubMedPubMedCentral

75.

Gagliano-Jucá T, Pencina KM, Ganz T, Travison TG, Kantoff PW, Nguyen PL, et al. Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer. Am J Physiol Endocrinol Metab. 2018;315:E1185-93. https://doi.org/10.1152/ajpendo.00272.2018.CrossRefPubMedPubMedCentral

76.

Marschner N, Trarbach T, Rauh J, Meyer D, Müller-Hagen S, Harde J, et al. Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project. Breast Cancer Res Treat. 2019;175:701-12. https://doi.org/10.1007/s10549-019-05197-w.CrossRefPubMedPubMedCentral

77.

Tanguturi SK, Alexander BM. Neurologic complications of radiation therapy. Neurol Clin. 2018;36:599-625. https://doi.org/10.1016/j.ncl.2018.04.012.CrossRefPubMed

78.

Couwenberg AM, Burbach JPM, van Grevenstein WMU, Smits AB, Consten ECJ, Schiphorst AHW, et al. Effect of neoadjuvant therapy and rectal surgery on health-related quality of life in patients with rectal cancer during the first 2 years after diagnosis. Clin Colorectal Cancer. 2018;17:e499-512. https://doi.org/10.1016/j.clcc.2018.03.009.CrossRefPubMed

79.

Fosså SD, Bengtsson T, Borre M, Ahlgren G, Rannikko A, Dahl AA. Reduction of quality of life in prostate cancer patients: experience among 6200 men in the Nordic countries. Scand J Urol. 2016;50:330-7. https://doi.org/10.1080/21681805.2016.1201859.CrossRefPubMed

80.

Kamal M, Rosenthal DI, Batra A, Volpe S, Elgohari B, Goepfert RP, et al. Fatigue following radiation therapy in nasopharyngeal cancer survivors: a dosimetric analysis incorporating patient report and observer rating. Radiother Oncol. 2019;133:35-42. https://doi.org/10.1016/j.radonc.2018.12.023.CrossRefPubMedCentral

81.

Arnaud J, Penel N, Ladsous M, Christine Vantyghem M, Christine DC. Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders. Crit Rev Oncol Hematol. 2019. https://doi.org/10.1016/j.critrevonc.2019.05.015.CrossRef

82.

Kishan AU, Wang P-C, Sharif J, Kupelian PA, Steinberg ML, McCloskey SA. Clinical indicators of psychosocial distress predict for acute radiation-induced fatigue in patients receiving adjuvant radiation therapy for breast cancer: an analysis of patient-reported outcomes. Int J Radia Oncol Biol Physics. 2016;95:946-55. https://doi.org/10.1016/j.ijrobp.2016.01.062.CrossRef

83.

Lukkahatai N, Saligan LN. Association of catastrophizing and fatigue: a systematic review. J Psychosom Res. 2013;74:100-9. https://doi.org/10.1016/j.jpsychores.2012.11.006.CrossRefPubMed

84.

•• Mustian KM, Alfano CM, Heckler C, Kleckner AS, Kleckner IR, Leach CR, et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol. 2017;3:961-8. https://doi.org/10.1001/jamaoncol.2016.6914. Results from meta-analysis showed that exercise had the greatest effect in reducing CRF, followed by psychological interventions. Pharmacologic interventions were least effective.CrossRefPubMedPubMedCentral

85.

• Thekdi SM, Trinidad A, Roth A. Psychopharmacology in cancer. Curr Psychiatry Rep. 2015;17:529. https://doi.org/10.1007/s11920-014-0529-x. Brief overview of the use and contra-indication of antidepressants and psychostimulants for cancer-related fatigue.CrossRefPubMed

86.

Qu D, Zhang Z, Yu X, Zhao J, Qiu F, Huang J. Psychotropic drugs for the management of cancer-related fatigue: a systematic review and meta-analysis. Eur J Cancer Care. 2016;25:970-9. https://doi.org/10.1111/ecc.12397.CrossRef

87.

Rojí R, Centeno C. The use of methylphenidate to relieve fatigue. Curr Opin Support Palliat Care. 2017;11:299-305. https://doi.org/10.1097/spc.0000000000000296.CrossRefPubMed

88.

•• Tomlinson D, Robinson PD, Oberoi S, Cataudella D, Culos-Reed N, Davis H, et al. Pharmacologic interventions for fatigue in cancer and transplantation: a meta-analysis. Curr Oncol. 2018;25:e152-67. https://doi.org/10.3747/co.25.3883. Methylphenidate and erythropoietin are associated with reduced CRF but safety concerns could limit their use.CrossRefPubMedPubMedCentral

89.

Andrew BN, Guan NC, Jaafar NRN. The use of methylphenidate for physical and psychological symptoms in cancer patients: a review. Curr Drug Targets. 2018;19:877-87. https://doi.org/10.2174/1389450118666170317162603.CrossRefPubMed

90.

Storebo OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2015:CD009885. https://doi.org/10.1002/14651858.CD009885.pub2.

91.

Murillo-Rodríguez E, Barciela Veras A, Barbosa Rocha N, Budde H, Machado S. An overview of the clinical uses, pharmacology, and safety of modafinil. ACS Chem Neurosci. 2018;9:151-8. https://doi.org/10.1021/acschemneuro.7b00374.CrossRefPubMed

92.

Heckler CE, Garland SN, Peoples AR, Perlis ML, Shayne M, Morrow GR, et al. Cognitive behavioral therapy for insomnia, but not armodafinil, improves fatigue in cancer survivors with insomnia: a randomized placebo-controlled trial. Support Care Cancer. 2016;24:2059-66. https://doi.org/10.1007/s00520-015-2996-y.CrossRefPubMed

93.

• Grassi L, Nanni MG, Rodin G, Li M, Caruso R. The use of antidepressants in oncology: a review and practical tips for oncologists. Ann Oncol. 2017;29:101-11. https://doi.org/10.1093/annonc/mdx526. Outlines the characteristics and safety issues of antidepressants suitable for use on CRF.CrossRef

94.

• Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. J Clin Oncol. 2019;37:1336-51. https://doi.org/10.1200/jco.18.02142. Updated ASCO/ASH recommendations on the use of erythropoiesis-stimulating agents.CrossRefPubMed

95.

• Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines†. Ann Oncol. 2018;29:iv96-iv110. https://doi.org/10.1093/annonc/mdx758. Updated ESMO guidelines for the management of anemia and iron deficiency.CrossRefPubMed

96.

• Kelley GA, Kelley KS. Exercise and cancer-related fatigue in adults: a systematic review of previous systematic reviews with meta-analyses. BMC Cancer. 2017;17:693-17. https://doi.org/10.1186/s12885-017-3687-5. Meta-analysis of previous systematic reviews assessing efficacy of aerobic and/or resistance training for CRF. Results are inconclusive although evidence supports that exercise does not increase CRF.CrossRefPubMedPubMedCentral

97.

• Lipsett A, Barrett S, Haruna F, Mustian K, O'Donovan A. The impact of exercise during adjuvant radiotherapy for breast cancer on fatigue and quality of life: a systematic review and meta-analysis. Breast. 2017;32:144-55. https://doi.org/10.1016/j.breast.2017.02.002. This meta-analysis showed that exercise during adjuvant radiotherapy can be beneficial in reducing CRF in breast cancer survivors.CrossRefPubMed

98.

• Hilfiker R, Meichtry A, Eicher M, Nilsson Balfe L, Knols RH, Verra ML, et al. Exercise and other non-pharmaceutical interventions for cancer-related fatigue in patients during or after cancer treatment: a systematic review incorporating an indirect-comparisons meta-analysis. Br J Sports Med. 2018;52:651-8. https://doi.org/10.1136/bjsports-2016-096422. The efficacy of various non-pharmacologic interventions are assessed and ranked using Bayesian approach. Survivors who are fatigued can have option of deciding on an intervention that best suits them.CrossRefPubMed

99.••

Knips L, Bergenthal N, Streckmann F, Monsef I, Elter T, Skoetz N. Aerobic physical exercise for adult patients with haematological malignancies. Cochrane Database Syst Rev. 2019. https://doi.org/10.1002/14651858.CD009075.pub3. Moderate- to very low-quality evidence is available for the efficacy of aerobic exercise on CRF in adult survivors of hematological cancers.

100.•

Kessels E, Husson O, van der Feltz-Cornelis CM. The effect of exercise on cancer-related fatigue in cancer survivors: a systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2018;14:479-94. https://doi.org/10.2147/NDT.S150464. Aerobic interventions with high adherence levels showed the most effect in reducing CRF.CrossRefPubMedPubMedCentral

101.

Carli F, Gillis C, Scheede-Bergdahl C. Promoting a culture of prehabilitation for the surgical cancer patient. Acta Oncol. 2017;56:128-33. https://doi.org/10.1080/0284186X.2016.1266081.CrossRefPubMed

102.

Macmillan Cancer Support. Prehabilitation for people with cancer: Principles and guidance for prehabilitation within the management and support of people with cancer. 2019. https://www.macmillan.org.uk/assets/prehabilitation-guidance-for-people-with-cancer.pdf. Accessed 9 October 2019.

103.

Treanor C, Kyaw T, Donnelly M. An international review and meta-analysis of prehabilitation compared to usual care for cancer patients. J Cancer Surviv. 2018;12:64-73. https://doi.org/10.1007/s11764-017-0645-9.CrossRefPubMed

104.

Purcell A, Fleming J, Burmeister B, Bennett S, Haines T. Is education an effective management strategy for reducing cancer-related fatigue? Support Care Cancer. 2011;19:1429-39. https://doi.org/10.1007/s00520-010-0970-2.CrossRefPubMed

105.

Agasi-Idenburg CS, Zuilen MK-V, Westerman MJ, CJA P, Aaronson NK, Stuiver MM. “I am busy surviving” - Views about physical exercise in older adults scheduled for colorectal cancer surgery. J Geriatr Oncol. 2019. https://doi.org/10.1016/j.jgo.2019.05.001.

106.

Giles C, Cummins S. Prehabilitation before cancer treatment. BMJ. 2019;366:l5120. https://doi.org/10.1136/bmj.l5120.CrossRefPubMed

107.

Abdin S, Lavallee JF, Faulkner J, Husted M. A systematic review of the effectiveness of physical activity interventions in adults with breast cancer by physical activity type and mode of participation. Psychooncology. 2019;28:1381-93. https://doi.org/10.1002/pon.5101.CrossRefPubMed

108.

• Tian L, Lu HJ, Lin L, Hu Y. Effects of aerobic exercise on cancer-related fatigue: a meta-analysis of randomized controlled trials. Support Care Cancer. 2016;24:969-83. https://doi.org/10.1007/s00520-015-2953-9. This systematic review concluded that aerobic exercise in the post-adjuvant treatment phase, is effective for CRF.CrossRefPubMed

109.

Witlox L, Hiensch AE, Velthuis MJ, Steins Bisschop CN, Los M, Erdkamp FLG, et al. Four-year effects of exercise on fatigue and physical activity in patients with cancer. BMC Med. 2018;16:86. https://doi.org/10.1186/s12916-018-1075-x.CrossRefPubMedPubMedCentral

110.

Carlson LE. Mindfulness-based interventions for coping with cancer. Ann N Y Acad Sci. 2016;1373:5-12. https://doi.org/10.1111/nyas.13029.CrossRefPubMed

111.

• Duong N, Davis H, Robinson PD, Oberoi S, Cataudella D, Culos-Reed SN, et al. Mind and body practices for fatigue reduction in patients with cancer and hematopoietic stem cell transplant recipients: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017;120:210-6. https://doi.org/10.1016/j.critrevonc.2017.11.011. Mindfulness-based and relaxation interventions were most effective in reducing CRF.CrossRefPubMed

112.

• Haller H, Winkler MM, Klose P, Dobos G, Kümmel S, Cramer H. Mindfulness-based interventions for women with breast cancer: an updated systematic review and meta-analysis. Acta Oncol. 2017;56:1665-76. https://doi.org/10.1080/0284186X.2017.1342862. This meta-analysis concluded that mindfulness-based interventions may provide short-term relief for CRF in breast cancer survivors.CrossRefPubMed

113.••

Schell LK, Monsef I, Wöckel A, Skoetz N. Mindfulness-based stress reduction for women diagnosed with breast cancer. Cochrane Database Syst Rev. 2019. https://doi.org/10.1002/14651858.CD011518.pub2. The benefits of mindfulness-based interventions on CRF are short-term and do not extend beyond end of intervention.

114.•

Bennett S, Pigott A, Beller EM, Haines T, Meredith P, Delaney C. Educational interventions for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. 2016. https://doi.org/10.1002/14651858.CD008144.pub2. Educational interventions may have small effects in reducing CRF and could be better provided in combination with other interventions.

115.

•• Cramer H, Lauche R, Klose P, Lange S, Langhorst J, Dobos GJ. Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. Cochrane Database Syst Rev. 2017;1:CD010802. https://doi.org/10.1002/14651858.CD010802.pub2. Moderate quality evidence suggests that yoga could reduce CRF.CrossRefPubMed

116.

Danhauer SC, Addington EL, Cohen L, Sohl SJ, Van Puymbroeck M, Albinati NK, et al. Yoga for symptom management in oncology: a review of the evidence base and future directions for research. Cancer. 2019;125:1979-89. https://doi.org/10.1002/cncr.31979.CrossRefPubMed

117.

•• Greenlee H, DuPont-Reyes MJ, Balneaves LG, Carlson LE, Cohen MR, Deng G, et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin. 2017;67:194-232. https://doi.org/10.3322/caac.21397. Integrative therapies recommended for management of CRF received no higher than a 'C' grade on strength of evidence.CrossRefPubMedPubMedCentral

118.

Klein PJ, Schneider R, Rhoads CJ. Qigong in cancer care: a systematic review and construct analysis of effective qigong therapy. Support Care Cancer. 2016;24:3209-22. https://doi.org/10.1007/s00520-016-3201-7.CrossRefPubMed

119.

Lin W-F, Zhong M-F, Zhou Q-H, Zhang Y-R, Wang H, Zhao Z-H, et al. Efficacy of complementary and integrative medicine on health-related quality of life in cancer patients: a systematic review and meta-analysis. Cancer Manag Res. 2019;11:6663-80. https://doi.org/10.2147/CMAR.S195935.CrossRefPubMedPubMedCentral

120.

• Wayne PM, Lee MS, Novakowski J, Osypiuk K, Ligibel J, Carlson LE, et al. Tai chi and qigong for cancer-related symptoms and quality of life: a systematic review and meta-analysis. J Cancer Surviv. 2018;12:256-67. https://doi.org/10.1007/s11764-017-0665-5. Although tai-chi seems effective in reducing CRF, no definite conclusion can be drawn as current studies have issues with sample size and methodology.CrossRefPubMed

121.

• Zeng Y, Xie X, Cheng ASK. Qigong or tai chi in cancer care: an updated systematic review and meta-analysis. Curr Oncol Rep. 2019;21:48-6. https://doi.org/10.1007/s11912-019-0786-2. Qigong/tai-chi shows promise in reducing CRF but conclusions of its effectiveness is not definitive.CrossRefPubMed

122.

Song S, Yu J, Ruan Y, Liu X, Xiu L, Yue X. Ameliorative effects of tai chi on cancer-related fatigue: a meta-analysis of randomized controlled trials. Support Care Cancer. 2018;26:2091-102. https://doi.org/10.1007/s00520-018-4136-y.CrossRefPubMed

123.

Zhang Y, Lin L, Li H, Hu Y, Tian L. Effects of acupuncture on cancer-related fatigue: a meta-analysis. Support Care Cancer. 2018;26:415-25. https://doi.org/10.1007/s00520-017-3955-6.CrossRefPubMed

124.

• Shin ES, Seo KH, Lee SH, Jang JE, Jung YM, Kim MJ, et al. Massage with or without aromatherapy for symptom relief in people with cancer. Cochrane Database Syst Rev. 2016;6:CD009873. https://doi.org/10.1002/14651858.CD009873.pub3. Massage was not associated with reduced CRF.CrossRef

125.

Kinkead B, Schettler PJ, Larson ER, Carroll D, Sharenko M, Nettles J, et al. Massage therapy decreases cancer-related fatigue: results from a randomized early phase trial. Cancer. 2018;124:546-54. https://doi.org/10.1002/cncr.31064.CrossRefPubMed

126.

Schmidt ME, Wiskemann J, Armbrust P, Schneeweiss A, Ulrich CM, Steindorf K. Effects of resistance exercise on fatigue and quality of life in breast cancer patients undergoing adjuvant chemotherapy: a randomized controlled trial. Int J Cancer. 2015;137:471-80. https://doi.org/10.1002/ijc.29383.CrossRefPubMed

127.

Liu L, Marler MR, Parker BA, Jones V, Johnson S, Cohen-Zion M, et al. The relationship between fatigue and light exposure during chemotherapy. Support Care Cancer. 2005;13:1010-7. https://doi.org/10.1007/s00520-005-0824-5.CrossRefPubMedPubMedCentral

128.

Johnson JA, Garland SN, Carlson LE, Savard J, Simpson JSA, Ancoli-Israel S, et al. The LITE study: rationale and protocol for a randomized controlled trial of light therapy for cancer-related fatigue in cancer survivors. Contemp Clin Trials. 2016;49:166-73. https://doi.org/10.1016/j.cct.2016.07.004.CrossRefPubMed

129.

Ormel HL, van der Schoot GGF, Sluiter WJ, Jalving M, Gietema JA, Walenkamp AME. Predictors of adherence to exercise interventions during and after cancer treatment: a systematic review. Psychooncology. 2018;27:713-24. https://doi.org/10.1002/pon.4612.CrossRefPubMedPubMedCentral

130.

Johnson JA, Garland SN, Carlson LE, Savard J, Simpson JSA, Ancoli-Israel S, et al. Bright light therapy improves cancer-related fatigue in cancer survivors: a randomized controlled trial. J Cancer Surviv. 2018;12:206-15. https://doi.org/10.1007/s11764-017-0659-3.CrossRefPubMed

131.

Starreveld DEJ, Daniels LA, Valdimarsdottir HB, Redd WH, de Geus JL, Ancoli-Israel S, et al. Light therapy as a treatment of cancer-related fatigue in (non-)Hodgkin lymphoma survivors (SPARKLE trial): study protocol of a multicenter randomized controlled trial. BMC Cancer. 2018;18:880. https://doi.org/10.1186/s12885-018-4746-2.CrossRefPubMedPubMedCentral

132.

Leggett S, Koczwara B, Miller M. The impact of complementary and alternative medicines on cancer symptoms, treatment side effects, quality of life, and survival in women with breast cancer--a systematic review. Nutr Cancer. 2015;67:373-91. https://doi.org/10.1080/01635581.2015.1004731.CrossRefPubMed

133.

• Luo C, Xu X, Wei X, Feng W, Huang H, Liu H, et al. Natural medicines for the treatment of fatigue: bioactive components, pharmacology, and mechanisms. Pharmacol Res. 2019;148:104409. https://doi.org/10.1016/j.phrs.2019.104409. Of the natural medicines, ginseng is the most researched for its efficacy in reducing CRF. However, evidence of its effect is weak.CrossRefPubMed

134.

Inglis JE, Lin P-J, Kerns SL, Kleckner IR, Kleckner AS, Castillo DA, et al. Nutritional interventions for treating cancer-related fatigue: a qualitative review. Nutr Cancer. 2019;71:21-40. https://doi.org/10.1080/01635581.2018.1513046.CrossRefPubMedPubMedCentral

135.

Pereira PTVT, Reis AD, Diniz RR, Lima FA, Leite RD, da Silva MCP, et al. Dietary supplements and fatigue in patients with breast cancer: a systematic review. Breast Cancer Res Treat. 2018;171:515-26. https://doi.org/10.1007/s10549-018-4857-0.CrossRefPubMed

136.

Arring NM, Millstine D, Marks LA, Nail LM. Ginseng as a treatment for fatigue: a systematic review. J Altern Complement Med. 2018;24:624-33. https://doi.org/10.1089/acm.2017.0361.CrossRefPubMed

137.

Sette CVM, Ribas de Alcântara BB, JHM S, Cruz FM, Cubero DIG, Pianowski LF, et al. Purified dry Paullinia cupana (PC-18) extract for chemotherapy-induced fatigue: results of two double-blind randomized clinical trials. J Diet Suppl. 2018;15:673-83. https://doi.org/10.1080/19390211.2017.1384781.CrossRefPubMed

138.

Buffart LM, Sweegers MG, May AM, Chinapaw MJ, van Vulpen JK, Newton RU, et al. Targeting exercise interventions to patients with cancer in need: an individual patient data meta-analysis. J Natl Cancer Inst. 2018;110:1190-200. https://doi.org/10.1093/jnci/djy161.CrossRefPubMedPubMedCentral

Titel: Cancer-Related Fatigue: Causes and Current Treatment Options
verfasst von: Melissa S.Y. Thong
Cornelis J. F. van Noorden
Karen Steindorf
Volker Arndt
Publikationsdatum: 01.02.2020
Verlag: Springer New York
Erschienen in: Current Treatment Options in Oncology / Ausgabe 2/2020
Print ISSN: 1527-2729
Elektronische ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-020-0707-5

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Cancer-Related Fatigue: Causes and Current Treatment Options

Opinion statement

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

Das sind die führenden Symptome junger Darmkrebspatienten

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Opinion statement

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Neoadjuvant Immunotherapy for Locally Advanced Melanoma

Patient Spirituality as a Component of Supportive Care: Assessment and Intervention

Nausea and Vomiting in Advanced Cancer

Dedifferentiated Liposarcoma: Systemic Therapy Options

Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia

How Effective Is Palliative Care in Improving Patient Outcomes?

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

Das sind die führenden Symptome junger Darmkrebspatienten

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

Update Onkologie